| Title |
Cost-Effectiveness of Apixaban Compared with Warfarin for Stroke Prevention in Atrial Fibrillation
|
|---|---|
| Published in |
PLOS ONE, October 2012
|
| DOI | 10.1371/journal.pone.0047473 |
| Pubmed ID | |
| Authors |
Soyon Lee, Rachel Mullin, Jon Blazawski, Craig I. Coleman |
| Abstract |
Apixaban was shown to be superior to adjusted-dose warfarin in preventing stroke or systemic embolism in patients with atrial fibrillation (AF) and at least one additional risk factor for stroke, and associated with reduced rates of hemorrhage. We sought to determine the cost-effectiveness of using apixaban for stroke prevention. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Egypt | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 149 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 3 | 2% |
| France | 2 | 1% |
| Colombia | 1 | <1% |
| Denmark | 1 | <1% |
| Slovenia | 1 | <1% |
| Unknown | 141 | 95% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 24 | 16% |
| Researcher | 23 | 15% |
| Student > Bachelor | 19 | 13% |
| Other | 12 | 8% |
| Student > Doctoral Student | 12 | 8% |
| Other | 31 | 21% |
| Unknown | 28 | 19% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 70 | 47% |
| Pharmacology, Toxicology and Pharmaceutical Science | 13 | 9% |
| Economics, Econometrics and Finance | 10 | 7% |
| Mathematics | 4 | 3% |
| Agricultural and Biological Sciences | 3 | 2% |
| Other | 18 | 12% |
| Unknown | 31 | 21% |